Novo Nordisk and Valo Health Expand AI Partnership for Drug Discovery
Danish pharmaceutical company Novo Nordisk and US technology company Valo Health announced on January 8 an expansion of their 2023 agreement to discover and develop treatments for obesity, type 2 diabetes, and cardiovascular disease. The collaboration leverages Valo's human dataset and AI-powered computational capabilities. Also Read: AMD Invests in Absci to Accelerate AI-Driven Drug Discovery Initial Agreement Novo and Valo initially partnered in September 2023 in an agreement to develop... Read More